Stockreport

HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab

HOOKIPA Pharma Inc.  (HOOK) 
Last hookipa pharma inc. earnings: 3/19 07:00 am Check Earnings Report
PDF Phase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPS [Read more]